Dhanushki Wickramarachchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dhanushki Wickramarachchi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Afka Deen
Nutritional Biochemistry Program, National Institute of Fundamental Studies
1 shared publication - Isuri Rathnayaka
Nutritional Biochemistry Program, National Institute of Fundamental Studies
1 shared publication - Mallique Qader
Institute for Tuberculosis Research, Pharmacognosy Institute, and Department of Pharmaceutical Sciences, Retzky College of Pharmacy, University of Illinois Chicago, Chicago, IL, 60612, United States
1 shared publication - Mostafa E. Rateb
School of Computing, Engineering and Physical Sciences, University of the West of Scotland, Paisley PA1 2BE, UK
1 shared publication - Pathumi Ariyarathna
Nutritional Biochemistry Program, National Institute of Fundamental Studies
1 shared publication - Rizliya Visvanathan
Department of Nutrition, Dietetics and Food, Monash University, Clayton, VIC, 3168, Australia
1 shared publication
Latest Publications
- 22 January 2025
- Published by Taylor & Francis in Natural Product Research
- Vol. 40 (11) , 3134-3142
In vitro anti-diabetic potential of medicinal herbs commonly used in the Ayurvedic system of Sri Lanka with comprehensive metabolite profiling of Phyllanthus emblica using GC-MS and LC-HRMS
This study assessed the in vitro anti-diabetic potential and bioactive constituents of ten Sri Lankan medicinal herbs. Initial screening of aqueous extracts for starch-digesting enzyme inhibition prioritised three plants with notable activity (p ≤ 0.05), for further assessment using methanolic extracts: Phyllanthus emblica (PE), Cassia auriculata (CA), and Hemidesmus indicus (HI). The selected plants were tested for starch-digesting enzyme inhibition, cytotoxicity, and bioactive metabolite identification, with PE subjected to GC-MS and LC-HRMS analyses. All three extracts contained alkaloids, flavonoids, tannins, and terpenoids, except saponins and steroids in PE. GC-MS analysis of PE annotated ten compounds, eight with anti-diabetic properties, while LC-HRMS annotated thirty metabolites, including fourteen anti-diabetic compounds. Cell viability assessments confirmed the non-toxic nature of PE, CA, and HI. The significant enzyme inhibition and non-toxic nature of PE highlight its potential to treat type 2 diabetes. Further in vivo and clinical studies are essential to determining effective dosage and toxicity levels.
- 22 January 2025
- Published by Taylor & Francis in Natural Product Research
- Vol. 40 (11) , 3134-3142
In vitro anti-diabetic potential of medicinal herbs commonly used in the Ayurvedic system of Sri Lanka with comprehensive metabolite profiling of Phyllanthus emblica using GC-MS and LC-HRMS
This study assessed the in vitro anti-diabetic potential and bioactive constituents of ten Sri Lankan medicinal herbs. Initial screening of aqueous extracts for starch-digesting enzyme inhibition prioritised three plants with notable activity (p ≤ 0.05), for further assessment using methanolic extracts: Phyllanthus emblica (PE), Cassia auriculata (CA), and Hemidesmus indicus (HI). The selected plants were tested for starch-digesting enzyme inhibition, cytotoxicity, and bioactive metabolite identification, with PE subjected to GC-MS and LC-HRMS analyses. All three extracts contained alkaloids, flavonoids, tannins, and terpenoids, except saponins and steroids in PE. GC-MS analysis of PE annotated ten compounds, eight with anti-diabetic properties, while LC-HRMS annotated thirty metabolites, including fourteen anti-diabetic compounds. Cell viability assessments confirmed the non-toxic nature of PE, CA, and HI. The significant enzyme inhibition and non-toxic nature of PE highlight its potential to treat type 2 diabetes. Further in vivo and clinical studies are essential to determining effective dosage and toxicity levels.